FENNEC PHARMACEUTICALS INC. - 8-K Filing

Fennec Pharmaceuticals announced positive results from Phase 2 STS-J01 trial showing PEDMARK significantly reduced cisplatin-induced hearing loss.

SEC EDGAR ·

Tickers: $FENC

Read the full article at SEC EDGAR

More Regulatory news